HHS
Harte Hanks, Inc.
There isn't enough reported data to score HHS yet.
RDDT
Reddit, Inc.
RDDT's fundamentals are strong: revenue grew 62% and its operating margin rose 16 points to 29%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HHS's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
RDDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
RDDT's revenue, profitability, cash flow and balance sheet are all currently healthy.
HHS PE Valuation
HHS has no meaningful PE right now: it lost money over the past year.
RDDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $99.55 | — |
| Current | 20x | $99.55 | — |
| Cheap | 35x | $171 | +72% |
| Fair | 46x | $228 | +129% |
| Expensive | 53x | $262 | +163% |
Historical ranges are pointers, not guarantees.
RDDT's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
HHS Forward outlook
There aren't enough analyst estimates for HHS to show an outlook.
RDDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect strong earnings and revenue growth for RDDT, with profitability improving. However, they disagree widely on these estimates.
HHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.76 | -$0.37 |
| Q1 2026 | -$0.14 | +$4.04 |
| Q4 2025 | -$0.11 | +$4.04 |
| Q3 2025 | -$0.72 | +$3.38 |
| Q2 2025 | -$0.39 | +$3.65 |
| Q1 2025 | -$4.18 | -$4.06 |
| Q4 2024 | -$4.15 | -$3.94 |
| Q3 2024 | -$4.10 | -234% |
RDDT has the stronger earnings trend. Trailing diluted EPS is down 295% for HHS versus RDDT down 39%.
RDDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.32 | +29% |
| Q3 2024 | -$7.98 | -$7.17 |
| Q2 2024 | -$8.19 | -$7.15 |
| Q1 2024 | -$8.38 | -$7.25 |
| Q4 2023 | -$0.56 | +$0.41 |
| Q3 2023 | -$0.81 | -$0.02 |
| Q2 2023 | -$1.04 | -$0.48 |
| Q1 2023 | -$1.13 | -$0.48 |
| Q4 2022 | -$0.97 | -$0.19 |
RDDT has returned to profit: it earned $4.90 per share over the past year, after losing money the year before.
HHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $38M | -1.7% |
| Q1 2026 | $37.3M | -10% |
| Q4 2025 | $39.9M | -15% |
| Q3 2025 | $39.5M | -17% |
| Q2 2025 | $38.6M | -14% |
| Q1 2025 | $41.6M | -8.6% |
| Q4 2024 | $47.1M | -4.8% |
| Q3 2024 | $47.6M | +1.1% |
HHS's revenue has slid since its 2022 peak: $38M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -12% | -12 points |
| Q1 2026 | -2.1% | -2 points |
| Q4 2025 | -0.3% | +3 points |
| Q3 2025 | 1.3% | -2.7 points |
| Q2 2025 | 0.1% | -3 points |
| Q1 2025 | -0.1% | -0.9 points |
| Q4 2024 | -3.3% | +1.3 points |
| Q3 2024 | 4% | -2.2 points |
HHS's operating margin was −12% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
RDDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895M | +53% |
| Q2 2026 | $804.9M | +61% |
| Q1 2026 | $663.4M | +69% |
| Q4 2025 | $725.6M | +70% |
| Q3 2025 | $584.9M | +68% |
| Q2 2025 | $499.6M | +78% |
| Q1 2025 | $392.4M | +61% |
| Q4 2024 | $427.7M | +71% |
RDDT has the edge over HHS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +5.5 points |
| Q2 2026 | 29% | +15 points |
| Q1 2026 | 28% | +27 points |
| Q4 2025 | 32% | +20 points |
| Q3 2025 | 24% | +22 points |
| Q2 2025 | 14% | +25 points |
| Q1 2025 | 1% | +244 points |
| Q4 2024 | 12% | +11 points |
RDDT has the edge over HHS on profitability, with a higher operating margin.
HHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$3M |
| Q1 2026 | -$922K | +$1K |
| Q4 2025 | -$686K | -120% |
| Q3 2025 | $2.2M | +$7M |
| Q2 2025 | -$5.1M | -648% |
| Q1 2025 | -$923K | +$5.3M |
| Q4 2024 | $3.4M | +13% |
| Q3 2024 | -$4.9M | -474% |
HHS has burned cash in six of the last eight quarters: −$1M over the past year, against −$7M the year before.
RDDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $362.6M | +98% |
| Q2 2026 | $260.7M | +135% |
| Q1 2026 | $311.2M | +146% |
| Q4 2025 | $263.6M | +196% |
| Q3 2025 | $183.1M | +161% |
| Q2 2025 | $110.8M | +308% |
| Q1 2025 | $126.6M | +333% |
| Q4 2024 | $89.2M | +$111.2M |
RDDT has the edge over HHS on cash generation, producing positive trailing cash flow while its opponent burns cash.
HHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +15K shares |
| 1 year | +0.7% | +49K shares |
| 3 years | -1% | -74K shares |
| 5 years | +3.3% | +238K shares |
| Available history | +18% | +1.1M shares |
HHS has 7M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $491,000 |
RDDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -169K shares |
| 1 year | -0.4% | -868K shares |
| 3 years | +24% | +38.5M shares |
| 5 years | +24% | +38.5M shares |
RDDT has the edge over HHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $234.6M |
| Q1 2026 | $5M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $4.2M |
| Q4 2022 | — |
HHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
HHS has more cash than debt.
RDDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -3.3x | Net Cash |
| Q2 2025 | -5.0x | Net Cash |
| Q1 2025 | -13.1x | Net Cash |
RDDT has more cash than debt.
HHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 72.7 | Neutral |
HHS's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
RDDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 6.5 | Oversold |
RDDT's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
HHS PE vs Communication Services Sector
| Metric | HHS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 16x | — |
HHS has no meaningful PE right now: it lost money over the past year.
RDDT PE vs Communication Services Sector
| Metric | RDDT | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 16x | 23% above |
| PE % | 5 | 23 | 18 pts below |
RDDT is trading at 20x earnings, a 23% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
HHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.21 | 4.3% below |
| 20 week MA | $3.66 | 10% above |
| 50 week MA | $3.14 | 28% above |
| 100 week MA | $3.70 | 8.9% above |
| 200 week MA | $5.54 | 27% below |
HHS has stronger trend alignment. HHS is above 3 of 5 weekly averages versus RDDT above 0 of 4.
RDDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.6 | 24% below |
| 20 week MA | $151.7 | 34% below |
| 50 week MA | $165.0 | 40% below |
| 100 week MA | $167.1 | 40% below |
RDDT is in a downtrend: it's below all four of its weekly moving averages, and 40% below its 100-week average.
HHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.46 | $2.55 | -26% |
| 2021 | $2.55 | $8.17 | +220% |
| 2022 | $8.17 | $11.5 | +41% |
| 2023 | $11.5 | $6.79 | -41% |
| 2024 | $6.79 | $5.38 | -21% |
| 2025 | $5.38 | $3.32 | -38% |
| 2026 YTD | $3.32 | $4.03 | +21% |
HHS has the edge over RDDT on returns for 2026, with the stronger performance.
RDDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $46.0 | $173.5 | +277% |
| 2025 | $173.5 | $225.8 | +30% |
| 2026 YTD | $225.8 | $99.6 | -56% |
RDDT has finished every year since 2024 higher, and it's down 56% so far in 2026.